CSPC Pharmaceutical's Out-Licensing Revenue Likely to be Sizeable Revenue Source -- Market Talk

Dow Jones03-31

0700 GMT - CSPC Pharmaceutical's out-licensing revenue is likely to be a sizeable revenue source for the company in 2025 and going forward, Nomura's Jialin Zhang says in a research report, as the brokerage raises the stock's target price to HK$6.55 from HK$6.48 with an unchanged buy rating. At its 2024 earnings call, management reiterated "positive sales growth" for 2025 due to potentially CNY1.5 billion in additional sales from newly-launched drugs and collaboration revenue, the analyst notes. Management is confident of maintaining the current out-licensing pace in coming years owing to the company's broad early-stage innovative drug portfolio. For central nervous system drugs, management expects positive growth for its 'NBP' products and around CNY1 billion of sales from its Mingfule drug, the analyst adds. (ronnie.harui@wsj.com)

(END) Dow Jones Newswires

March 31, 2025 03:00 ET (07:00 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2523596197?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-03-31 15:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2523596197","market":"other","top_or_hot":-1,"title":"CSPC Pharmaceutical's Out-Licensing Revenue Likely to be Sizeable Revenue Source -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0700 GMT - CSPC Pharmaceutical's out-licensing revenue is likely to be a sizeable revenue source for the company in 2025 and going forward, Nomura's Jialin Zhang says in a research report, as the brokerage raises the stock's target price to HK$6.55 from HK$6.48 with an unchanged buy rating. At its 2024 earnings call, management reiterated \"positive sales growth\" for 2025 due to potentially CNY1.5 billion in additional sales from newly-launched drugs and collaboration revenue, the analyst notes. Management is confident of maintaining the current out-licensing pace in coming years owing to the company's broad early-stage innovative drug portfolio. For central nervous system drugs, management expects positive growth for its 'NBP' products and around CNY1 billion of sales from its Mingfule drug, the analyst adds. (ronnie.harui@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 31, 2025 03:00 ET (07:00 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CSPC Pharmaceutical's Out-Licensing Revenue Likely to be Sizeable Revenue Source -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCSPC Pharmaceutical's Out-Licensing Revenue Likely to be Sizeable Revenue Source -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-03-31 15:00</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0700 GMT - CSPC Pharmaceutical's out-licensing revenue is likely to be a sizeable revenue source for the company in 2025 and going forward, Nomura's Jialin Zhang says in a research report, as the brokerage raises the stock's target price to HK$6.55 from HK$6.48 with an unchanged buy rating. At its 2024 earnings call, management reiterated \"positive sales growth\" for 2025 due to potentially CNY1.5 billion in additional sales from newly-launched drugs and collaboration revenue, the analyst notes. Management is confident of maintaining the current out-licensing pace in coming years owing to the company's broad early-stage innovative drug portfolio. For central nervous system drugs, management expects positive growth for its 'NBP' products and around CNY1 billion of sales from its Mingfule drug, the analyst adds. (ronnie.harui@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 31, 2025 03:00 ET (07:00 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01093","symbol_name":"石药集团","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2523596197","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2523596197","pubTimestamp":1743404400,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0700 GMT - CSPC Pharmaceutical's out-licensing revenue is likely to be a sizeable revenue source for the company in 2025 and going forward, Nomura's Jialin Zhang says in a research report, as the brokerage raises the stock's target price to HK$6.55 from HK$6.48 with an unchanged buy rating. At its 2024 earnings call, management reiterated \"positive sales growth\" for 2025 due to potentially CNY1.5 billion in additional sales from newly-launched drugs and collaboration revenue, the analyst notes. Management is confident of maintaining the current out-licensing pace in coming years owing to the company's broad early-stage innovative drug portfolio. For central nervous system drugs, management expects positive growth for its 'NBP' products and around CNY1 billion of sales from its Mingfule drug, the analyst adds. ","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"01093":"石药集团"},"translate_title":"石药集团的授权收入可能是可观的收入来源——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01093":0.9},"content_text":"0700 GMT - CSPC Pharmaceutical's out-licensing revenue is likely to be a sizeable revenue source for the company in 2025 and going forward, Nomura's Jialin Zhang says in a research report, as the brokerage raises the stock's target price to HK$6.55 from HK$6.48 with an unchanged buy rating. At its 2024 earnings call, management reiterated \"positive sales growth\" for 2025 due to potentially CNY1.5 billion in additional sales from newly-launched drugs and collaboration revenue, the analyst notes. Management is confident of maintaining the current out-licensing pace in coming years owing to the company's broad early-stage innovative drug portfolio. For central nervous system drugs, management expects positive growth for its 'NBP' products and around CNY1 billion of sales from its Mingfule drug, the analyst adds. (ronnie.harui@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 31, 2025 03:00 ET (07:00 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2523596197","isCrawlerRequest":true}